SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001683168-21-003521
Filing Date
2021-08-13
Accepted
2021-08-13 08:00:51
Documents
37
Period of Report
2021-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q FOR JUNE 30, 2021 cns_i10q-063021.htm   iXBRL 10-Q 461923
2 CERTIFICATION BY CHIEF EXECUTIVE OFFICER cns_ex3101.htm EX-31.1 6899
3 CERTIFICATION BY CHIEF FINANCIAL OFFICER cns_ex3102.htm EX-31.2 6945
4 CERTIFICATION OF CHIEF EXECUTIVE OFFICER cns_ex3201.htm EX-32.1 3217
5 CERTIFICATION OF CHIEF EXECUTIVE OFFICER cns_ex3202.htm EX-32.2 3405
  Complete submission text file 0001683168-21-003521.txt   2581440

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cnsp-20210630.xsd EX-101.SCH 22524
7 XBRL CALCULATION FILE cnsp-20210630_cal.xml EX-101.CAL 25656
8 XBRL DEFINITION FILE cnsp-20210630_def.xml EX-101.DEF 103161
9 XBRL LABEL FILE cnsp-20210630_lab.xml EX-101.LAB 206856
10 XBRL PRESENTATION FILE cnsp-20210630_pre.xml EX-101.PRE 164075
11 EXTRACTED XBRL INSTANCE DOCUMENT cns_i10q-063021_htm.xml XML 308476
Mailing Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027
Business Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027 1-800-946-9185 X701
CNS Pharmaceuticals, Inc. (Filer) CIK: 0001729427 (see all company filings)

IRS No.: 822318545 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39126 | Film No.: 211169779
SIC: 2834 Pharmaceutical Preparations